Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …

The COVID-19 (coronavirus disease 2019) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has led to loss of human life in millions and …

Influenza vaccines that confer broad and durable protection against diverse viral strains
would have a major effect on global health, as they would lessen the need for annual …

Currently, licensed seasonal influenza vaccines display variable vaccine effectiveness, and
there remains a need for novel vaccine platforms capable of inducing broader responses …

Wastewater monitoring can provide insights into respiratory disease occurrence in
communities that contribute to the wastewater system. Using daily measurements of RNA of …

Seasonal influenza viruses cause recurring global epidemics by continually evolving to
escape host immunity. The viral constraints and host immune responses that limit and drive …

Influenza vaccines could be improved by platforms inducing cross-reactive immunity.
Immunodominance of the influenza hemagglutinin (HA) head in currently licensed vaccines …

Vaccines are one of the most powerful technologies supporting public health. The adaptive
immune response induced by immunization arises following appropriate activation and …

In recent years, highly pathogenic avian influenza H5 subtype (HPAI H5) viruses have been
prevalent around the world in both avian and mammalian species, causing serious …